Meda Introduces Edluar For Insomnia

Meda Pharmaceuticals (Meda) has announced the commercial availability of Edluar (zolpidem tartrate sublingual tablets) in the US. Edluar is indicated for the short-term treatment of insomnia.

Sharon Clarke, president and general manager of Meda, said: “With the introduction of Edluar sublingual tablets, patients with insomnia who have trouble falling asleep now have another treatment option. We are pleased to be the company that brings this innovative new formulation to these patients.”

Harry Sacks, vice president of medical affairs at Meda, said: “Edluar combines the efficacy and safety profile of zolpidem tartrate — an agent used for 17 years — with a new sublingual formulation that is convenient for patients with short-term insomnia whose primary complaint is the inability to fall asleep.”

Edluar sublingual tablets contain the active ingredient zolpidem tartrate and have a pharmacokinetic profile characterized by rapid absorption.